N Chainani-Wu1, E Madden2, D Cox3, H Sroussi4, J Epstein5,6, S Silverman7. 1. Private practice in oral Medicine, Mountain View, CA, USA. 2. Northern California Institute for Research and Education (NCIRE), San Francisco, CA, USA. 3. Arthur A. Dugoni School of Dentistry, University of the Pacific, San Francisco, CA, USA. 4. College of Dentistry at the University of Illinois in Chicago, Chicago, IL, USA. 5. Cedars-Sinai Medical Center, Los Angeles, CA, USA. 6. City of Hope National Medical Center, Duarte, CA, USA. 7. University of California, San Francisco, CA, USA.
Abstract
OBJECTIVES: Accurate clinical identification of 'higher-risk' oral premalignant lesions or 'higher-risk' areas within lesions is important. Assessment methods that predict their presence have great utility. SUBJECTS AND METHODS: A cross-sectional, observational study enrolled a consecutive sample of consenting patients diagnosed with oral leukoplakia, erythroleukoplakia, or erythroplakia. Medical history, visual oral examination, ViziLite(®) examination, toluidine blue staining (TBlue(®) ), and finally a biopsy were completed in a single clinic visit. Seventy-seven of 100 examined lesions in 43 patients were biopsied. Sensitivity, specificity, and positive and negative predictive values were computed for visual examination, ViziLite(®) , and TBlue(®) using biopsy results as the gold standard. RESULTS: The sensitivity of TBlue(®) in detecting high-risk lesions (carcinoma in situ or carcinoma) was 94 (71-100, P < 0.0003) and specificity 45 (32-58, P < 0.53), while for carcinoma, sensitivity was 100 (54-100, P < 0.032) and specificity 39 (28-52, P < 0.097). The results of ViziLite(®) testing either by itself or in combination with the information from toluidine blue testing revealed low sensitivity for the detection of high-risk lesions. CONCLUSIONS: Clinical examination of leukoplakia, erythroplakia, or erythroleukoplakia lesions combined with toluidine blue staining may aid in the identification of severe dysplasia (carcinoma in situ) or carcinoma. This may help in determining whether, when, and where (the site within a lesion) a biopsy should be taken.
OBJECTIVES: Accurate clinical identification of 'higher-risk' oral premalignant lesions or 'higher-risk' areas within lesions is important. Assessment methods that predict their presence have great utility. SUBJECTS AND METHODS: A cross-sectional, observational study enrolled a consecutive sample of consenting patients diagnosed with oral leukoplakia, erythroleukoplakia, or erythroplakia. Medical history, visual oral examination, ViziLite(®) examination, toluidine blue staining (TBlue(®) ), and finally a biopsy were completed in a single clinic visit. Seventy-seven of 100 examined lesions in 43 patients were biopsied. Sensitivity, specificity, and positive and negative predictive values were computed for visual examination, ViziLite(®) , and TBlue(®) using biopsy results as the gold standard. RESULTS: The sensitivity of TBlue(®) in detecting high-risk lesions (carcinoma in situ or carcinoma) was 94 (71-100, P < 0.0003) and specificity 45 (32-58, P < 0.53), while for carcinoma, sensitivity was 100 (54-100, P < 0.032) and specificity 39 (28-52, P < 0.097). The results of ViziLite(®) testing either by itself or in combination with the information from toluidine blue testing revealed low sensitivity for the detection of high-risk lesions. CONCLUSIONS: Clinical examination of leukoplakia, erythroplakia, or erythroleukoplakia lesions combined with toluidine blue staining may aid in the identification of severe dysplasia (carcinoma in situ) or carcinoma. This may help in determining whether, when, and where (the site within a lesion) a biopsy should be taken.
Authors: Silvio Abati; Chiara Bramati; Stefano Bondi; Alessandra Lissoni; Matteo Trimarchi Journal: Int J Environ Res Public Health Date: 2020-12-08 Impact factor: 3.390
Authors: Munira Essat; Katy Cooper; Alice Bessey; Mark Clowes; James B Chilcott; Keith D Hunter Journal: Head Neck Date: 2022-01-29 Impact factor: 3.821
Authors: Lily Margoth Cedeño-Suárez; María Elisa Vega-Memije; Juan Carlos Cuevas-González; Adalberto Mosqueda-Taylor Journal: Autops Case Rep Date: 2021-03-12
Authors: Tanya Walsh; Richard Macey; Alexander R Kerr; Mark W Lingen; Graham R Ogden; Saman Warnakulasuriya Journal: Cochrane Database Syst Rev Date: 2021-07-20